Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report report published on Monday morning. The brokerage issued a hold rating on the medical research company’s stock.

Several other brokerages have also weighed in on CTSO. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research report on Tuesday, February 25th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Cytosorbents has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Performance

Shares of CTSO stock opened at $1.07 on Monday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.61. The stock’s 50-day moving average is $1.06 and its two-hundred day moving average is $1.04. The firm has a market cap of $58.51 million, a P/E ratio of -2.97 and a beta of 0.78.

Institutional Trading of Cytosorbents

Several large investors have recently made changes to their positions in CTSO. Renaissance Technologies LLC boosted its stake in Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after purchasing an additional 8,400 shares during the period. Northern Trust Corp increased its holdings in Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 16,701 shares in the last quarter. Skylands Capital LLC increased its holdings in Cytosorbents by 1.0% during the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after purchasing an additional 26,195 shares in the last quarter. Geode Capital Management LLC increased its holdings in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Cytosorbents in the 4th quarter valued at $30,000. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.